Source: Annual Congress 2010 - Biomarkers of asthma and COPD: recent advances
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. M. Beeh, C. Schilder, F. Wagner, F. Kanniess, I. Naudts, A. Hammann, J. Willers, M. Bachmann, W. Renner (Wiesbaden, Eisenach, Berlin, Luebeck, Rodgau, Germany; Schlieren, Switzerland). Late Breaking Abstract: TLR9 agonist CYT003-QbG10 is safe and efficacious in persistent allergic asthma: A double-blind, placebo-controlled phase II study. Eur Respir J 2010; 36: Suppl. 54, 3839

Member's Comments

No comment yet.

Related content which might interest you: RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019 Nasal beclomethasone plus loratadine in patients with rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 547s Year: 2007 Late-breaking abstract: Inhaled pan-selectin antagonist bimosiamose in COPD: A double-blind, randomized, placebo-controlled phase II study Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011 The effect of Theophylline in patients with allergic rhinitis: A double-blind, randomised, crossover study Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease Year: 2012 Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial Source: International Congress 2016 – Asthma management Year: 2016 Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 Risankizumab in severe asthma: A Phase IIa, placebo-controlled study Source: Virtual Congress 2020 – Asthma pharmacology: clinical trials and mechanistic insights Year: 2020 Efficacy of a short course of oral prednisolone for acute preschool viral-wheeze: a double-blind randomised placebo-controlled trial with stratification for systemic eosinophil priming Source: Eur Respir J 2003; 22: Suppl. 45, 388s Year: 2003 Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007 Efficacy of the Plasma Cluster® device in mild to moderate asthmatic children: A randomized, double-blind, placebo-controlled, proof-of-concept trial Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 A double-blind, double-dummy, randomized study of beclomethasone/formoterol versus fluticasone/salmeterol in treatment of moderate to severe asthma in Taiwan Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 A double blind randomised placebo controlled trial of the PPAR-gamma agonist pioglitazone in mild asthma Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Randomized, placebo-controlled studies of onset and duration of single-dose protection against exercise-induced bronchoconstriction (EIB) by montelukast Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005